TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3164333
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration surgical treatment with teflon membrane and chlorhexidine gluconate rinses
Study: 3164333
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment procedure (not specified in detail)
Study: 30402951
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BBR and rosuvastatin
Study: 25847579
Drug: Open-label Advair
Normalized name: Advair
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label Advair 250/50 twice daily for 8 weeks followed by randomization to Advair 250/50, Flovent 250, or Advair 100/50, given 1 inhalation twice daily.
Study: 23245760
Drug: GSK1521498 (mu-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (mu-opioid receptor antagonist)
Study: 18388845
Drug: Medicare-based algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicare-based algorithm for measuring chemotherapy-related toxicities
Study: 20578930
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg MPH
Study: 15994064
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg MPH
Study: 14578916
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment strategy (IND)
Study: 14578916
Drug: Stepwise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise treatment strategy (STEP)
Study: 9579942
Drug: Ganaxolone (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (doses ranging from 50 to 1,500 mg)
Study: 8265871
Drug: Broad-spectrum antimicrobial
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antimicrobial agents
Study: 8265871
Drug: Cytokines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines and other biological agents
Study: 8265871
Drug: Rational use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational use of antibiotics
Study: 28102582
Drug: Preventive Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Cognitive Therapy (PCT) with ADM tapering
Study: 28102582
Drug: Preventive Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Cognitive Therapy (PCT) with maintenance ADM
Study: 23255379
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive behaviour therapy (CBT) anger management intervention facilitated by lay therapists.
Study: 22024003
Drug: Family cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family cognitive behavioral therapy (FCBT)
Study: 16792052
Drug: Chlorhexidine-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-containing chewing gum (5 mg of chlorhexidine diacetate)
Study: 2423783
Drug: Indoramin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin (average dose of 50 mg every 12 h in 11 patients)
Study: 24083021
Drug: ALONE group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALONE group (only primary participant attended treatment)
Study: 21931073
Drug: manidipine/delapril combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: manidipine/delapril combination (10/30 mg/d)
Study: 21931073
Drug: delapril (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril (30 mg/d)
Study: 21931073
Drug: manidipine/delapril combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: manidipine/delapril combination
Study: 12588384
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood therapy (ABT)
Study: 10917114
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 1 mg daily
Study: 8768844
Drug: L-692,429 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-692,429 (0.05 mg/kg · h) for 24 h (low dose)
Study: 8768844
Drug: L-692,429 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-692,429 (0.1 mg/kg · h) for 12 h, then saline for 12 h (high dose)
Study: 8768844
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 μg/kg, iv) given 30 min before the end of each 24-h treatment
Study: 25928879
Drug: Pentaerythritol tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol tetranitrate (PETN) 80 mg/kg twice daily
Study: 19958867
Drug: Elinogrel (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinogrel (10, 20, 40, and 60 mg) administered as a single intravenous bolus before primary PCI
Study: 19958867
Drug: Elinogrel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elinogrel (all doses)
Study: 17108847
Drug: Testosterone patch
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch releasing 300 microg/24 hours
Study: 11300389
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg x ml(‐1)
Study: 11300389
Drug: Fentanyl combined
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl combined with ropivacaine 1 mg x ml(‐1)
Study: 10073511
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone
Study: 8688400
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (600 mg and 200 mg mifepristone)
Study: 2176947
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 10 micrograms min‐1 kg‐1
Study: 2176947
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 5 micrograms min‐1 kg‐1
Study: 2176947
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 2 micrograms min‐1 kg‐1
Study: 2176947
Drug: Control (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5% D‐glucose infusion)
Study: 24914549
Drug: Citalopram (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (30 mg/day)
Study: 17945035
Drug: Oxaliplatin 130
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m² on day 1 plus capecitabine 2000 mg/m² daily on days 1-15 (series I)
Study: 17945035
Drug: Oxaliplatin 85
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 85 mg/m² on day 1 plus capecitabine 2000 mg/m² daily on days 1-15 (series II)
Study: 8220940
Drug: naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen 500 mg twice daily for 2 weeks
Study: 3612776
Drug: No-treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment condition (Control)
Study: 29288788
Drug: Nephrostomy tract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrostomy tract infiltration (NTI) with 20 mL of 0.25% ropivacaine and epinephrine (n=32)
Study: 29288788
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block with 15 mL of 0.5% ropivacaine and epinephrine (n=32)
Study: 24767232
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy for 18 months
Study: 18616432
Drug: Morphine (only)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (only)
Study: 18616432
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and hydromorphone
Study: 15780537
Drug: Intranasal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17beta‐estradiol treatment (300 microg once daily)
Study: 11975863
Drug: DHEA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (300 mg)
Study: 8554932
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg salbutamol via nebuliser
Study: 1824806
Drug: Doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (mean dose 4.35 ± 0.2 mg/day)
Study: 31072841
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus early reconstructive surgery
Study: 31072841
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy plus delayed reconstructive surgery, if needed
Study: 26411271
Drug: Atropine infusion
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine infusion on admission.
Study: 16380589
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (10 mg/kg daily) administered 6 days prior to surgery through 6 days after surgery (13 days)
Study: 11475741
Drug: Artificial Shexiang
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial Shexiang Baoxin Pill (SXBXP)
Study: 11475741
Drug: Natural Shexiang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Shexiang Baoxin Pill (SXBXP)
Study: 2668784
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for both drugs)
Study: 28816728
Drug: All lens
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All lens types with any of the four care solutions
Study: 26005839
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in Veterans
Study: 18191265
Drug: Concomitant chemo
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemo radiation treatment
Study: 16314075
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia first
Study: 7681769
Drug: Synthetic porcine
Normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic porcine galanin IV, 500 micrograms in 100 mL
Study: 7681769
Drug: Saline IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline IV, 100 mL
Study: 2405141
Drug: Human surfactant
Normalized name: recombinant human surfactant protein D
DrugBank: Zelpultide alfa (DB18587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human surfactant treatment
Study: 31495382
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of alcohol (one standard drink)
Study: 31495382
Drug: g/kg dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: g/kg dosing of alcohol (controlling for gender)
Study: 26608256
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg daily)
Study: 24992552
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg once daily
Study: 15741004
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Amitriptyline and Fluvoxamine)
Study: 10561206
Drug: Low-dose chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chemotherapy (doxorubicin 20 mg/m(2), vincristine 1 mg/m(2) on day 1; cyclophosphamide 300 mg/m(2); methotrexate 25 mg/m(2); fluorouracil 600 mg/m(2) on days 29 and 36) plus tamoxifen 20 mg orally for 2 years
Study: 10561206
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg orally for 2 years
Study: 10561206
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (terminated group)
Study: 8568142
Drug: Oral cow
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cow milk challenges
Study: 6885683
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg tds
Study: 31962329
Drug: Traditional medicine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine-based diet and lifestyle recommendations for at least 3 months
Study: 31962329
Drug: Traditional medicine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine-based diet and lifestyle recommendations
Study: 11687542
Drug: Indomethacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (5 mg/kg) pretreatment
Study: 3070369
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg, 3 times p.o. in 12 h intervals starting on the 3rd day of life)
Study: 3070369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (22 VLBWI with comparable weight 1250 ± 154 g, gestational age 28.4 ± 1 weeks)
Study: 22672773
Drug: VAC(®) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC(®) therapy
Study: 22672773
Drug: Sorbalgon(®) therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbalgon(®) therapy
Study: 21584935
Drug: Propofol-ketamine combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-ketamine combination (Group K)
Study: 17257456
Drug: Cefdinir 300
Normalized name: cefdinir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir 300 mg BID for 10 days
Study: 17257456
Drug: Cephalexin 250
Normalized name: cephalexin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 250 mg QID for 10 days
Study: 15029134
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and aerobic exercise
Study: 25374138
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 μg/kg)
Study: 25374138
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 ml saline)
Study: 24620386
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (100 mL added to 0.9% saline for 3 days preoperatively)
Study: 24620386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Xuebijing injection)
Study: 21933609
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg per day for at least 3 days before procedure)
Study: 16813587
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with oxaliplatin and irinotecan
Study: 16813587
Drug: Targeted agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted agents bevacizumab and cetuximab
Study: 16813587
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy prior to preoperative CRT
Study: 9250454
Drug: Lys(B28), Pro(B29)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lys(B28), Pro(B29) human insulin analog (insulin lispro)
Study: 3613693
Drug: Buspirone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 25 mg
Study: 3613693
Drug: Buspirone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 50 mg
Study: 3613693
Drug: Buspirone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 100 mg
Study: 26057685
Drug: Original Youth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original Youth Fit For Life treatment
Study: 20683051
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of cisplatin-etoposide followed by topotecan (arm A)
Study: 20683051
Drug: Alternate administration
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate administration of cisplatin-etoposide and topotecan (arm B)
Study: 14522530
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with oral and enteral polymyxin E, tobramycin, and amphotericin B combined with an initial 4-day course of intravenous cefotaxime
Study: 11004613
Drug: OKTcdr4a 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKTcdr4a 225 mg/course (low dose)
Study: 11004613
Drug: OKTcdr4a 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKTcdr4a 750 mg/course (high dose)
Study: 11004613
Drug: OKTcdr4a 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKTcdr4a 750 mg/course (high dose) after initial treatment
Study: 11004613
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or low-dose OKTcdr4a followed by high-dose OKTcdr4a
Study: 9122545
Drug: Intact milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact milk (240 or 360 mL)
Study: 9122545
Drug: Hydrolyzed milk
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolyzed milk (240 or 360 mL)
Study: 1296499
Drug: ioversol 300
Normalized name: IOVERSOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioversol 300 mg/ml
Study: 1296499
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mg/ml
Study: 6691015
Drug: Weekly pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pelvic examinations starting at 37 weeks' gestation
Study: 29732651
Drug: 8 weekly
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weekly 2‐hr workshop sessions
Study: 24594499
Drug: Promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 25 mg intravenously
Study: 24594499
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg intravenously
Study: 20159180
Drug: ACIDFORM gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM gel (plus diaphragm)
Study: 11881521
Drug: Acamprosate 1332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 1332 to 1998 mg/day
Study: 11881521
Drug: Acamprosate with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate with psychosocial support (individual psychotherapy, group psychotherapy, behavioural therapy, brief intervention, family therapy)
Study: 11271401
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) prior to encoding
Study: 11271401
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg) at retrieval
Study: 11271401
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug state (DS) conditions
Study: 11271401
Drug: Same drug
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same drug state (SS)
Study: 11271401
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug state (DS)
Study: 9298634
Drug: Propentofylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline (300 mg, three times daily 1 hour before meals)
Study: 31758177
Drug: LID/ΔM2‐2/1030s vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LID/ΔM2‐2/1030s vaccine (105 PFU, intranasal)
Study: 29518747
Drug: High-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose n-3 PUFA treatment (2 g/d)
Study: 8644642
Drug: Pirsidomine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirsidomine 10 mg
Study: 8644642
Drug: Pirsidomine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirsidomine 20 mg
Study: 8644642
Drug: Pirsidomine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirsidomine 40 mg
Study: 24005170
Drug: Intratympanic steroid
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic steroid injection (ITS)
Study: 27881113
Drug: TAU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU + EFT (treatment as usual with integrated emotion-focused components)
Study: 18165461
Drug: Zolpidem extended
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended release 6.25 mg
Study: 12970227
Drug: Inhaled NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NO (20 ppm)
Study: 12970227
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil (1 mg/kg in 'cath laboratory', 0.25 mg/kg post op)
Study: 8675588
Drug: Ethanol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1.0 g/kg
Study: 8675588
Drug: Ethanol (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (any dose)
Study: 6517563
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir treatment
Study: 30508308
Drug: D/C/F/TAF split
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF split tablet (800/150/200/10 mg)
Study: 30508308
Drug: D/C/F/TAF crushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF crushed tablet (800/150/200/10 mg)
Study: 30508308
Drug: D/C/F/TAF whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: D/C/F/TAF whole tablet (800/150/200/10 mg)
Study: 26923235
Drug: Usual activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual activities of daily living (CTL group)
Study: 24527443
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alprazolam 0.5 mg and melatonin 3 mg
Study: 16876559
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (twice a week for 16 weeks)
Study: 12542428
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) using hand instruments
Study: 10804043
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg and 200 mg, Naproxen 500 mg twice daily
Study: 10804043
Drug: Celecoxib 25
Normalized name: celecoxib 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 25 to 400 mg twice daily
Study: 10804043
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 to 400 mg twice daily) and Naproxen 500 mg twice daily